Drug Trial Radar · NCT05622526
Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
Last checked: Nov 19, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Nov 1, 2025
Study completion Mar 1, 2026
Sponsor
- Lead sponsor
- Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules for the treatment of patients with NASH. The clinical trial has two stages: * Screening phase with a duration of 12 weeks to classify patients based on lifestyle modifications. * Treatment phase where patients will be randomized and stratified 2:1 to treatment: * Experimental for n=64 patients. * Placebo control for n=32 patients.
Conditions
- Patients With Nonalcoholic Steatohepatitis
Interventions
Group 1 or Experimental groupDrug
Capsules of fecal microbiota transplantation
Group 2 or Control groupOther
capsules of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with improvement of fat fraction by proton density by MRI and no worsening of activity or fibrosis.Time frame: 72 weeks
- number of adverse events (AEs), serious AEs, AEs resulting in discontinuation of study treatment, AEs of special interest, and changes in vital signs and laboratory valuesTime frame: 72 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.